ArticleGenes & genomics2025
ElF5B as a prognostic biomarker and its correlation with infiltrating immune cells in liver cancer.
Article in Genes & genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Subtype-specific clinical significance of RRM1 and RRM2 expression in non-small cell lung cancer: a TCGA-based analysis.Genes & genomics · 2026Article
- Integrated Bioinformatics and Multi-Omics Analysis of ZBTB40 Expression, Prognostic Relevance, and Regulatory Networks in Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe clinical behavior and molecular mechanisms of hepatocellular carcinoma (HCC) are intricate and highly variable, posing challenges for identifying novel targets in clinical research. The gene eukaryotic translation initiation factors 5B (EIF5B) plays a role in synthesize translation initiation complexes during the synthesis of eukaryotic proteins. MATERIALS AND
methodsWe conducted a comprehensive bioinformatics analysis using public databases including Tumor Immune Estimation Resource (TIMER), UALCAN, Kaplan-Meier plotter, LinkedOmics, and Gene Expression Profiling Interactive Analysis (GEPIA2).
resultsEIF5B expression in HCC samples was significantly higher than in normal liver tissue; additionally, EIF5B was highly in primary tumors, various stages of cancer and grades of tumor, and status of nodal metastasis. Higher EIF5B expression was also associated with diagnosis. EIF5B expression showed a positive correlation with B cells macrophages, myeloid dendritic cells, neutrophils, and CD4+ T cells. In the analysis of EIF5B co-expression networks, positively related genes of EIF5B were associated with a high hazard ration in different types of cancer, including HCC. In biological function of EIF5B, mainly plays including protein localization to chromosome, rRNA metabolic process, and ncRNA processing, etc.
conclusionThese results suggest that EIF5B may serve as a novel biomarker with prognostic relevance in HCC and provide insights into tumor immunology in HCC.
Indexed as
Identifiers
40853612What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.